- €189.42m
- €98.76m
- €6.86m
Brief: Transgene Says Its Novel Therapeutic Cancer Vaccine TG4001 Can Induce T-Cell Responses Against HPV16 Antigens
Brief: Transgene, BioInvent Report Positive Phase Ia Data On Oncolytic Virus BT-001 In Solid Tumours
Brief: BioInvent, Transgene Report Positive Phase 1a Data On Oncolytic Virus Bt-001 In Solid Tumors
Brief: Transgene Provides Q1 2023 Financial Position
Brief: Transgene Says AstraZeneca Terminates Oncolytic Virus R&D Collaboration
Brief: Transgene Appoints Alessandro Riva As Chairman And CEO
Brief: Transgene New Data Shows Cancer Vaccine Candidate Induced Strong And Specific Immune Responses Against Tumors
Brief: Transgene Says Preclinical Results Showing TG6050 Induces Tumor Regression
Brief: Transgene FY Net Loss Widens To EUR 32.8 Mln
Refinitiv Newscasts - Reuters Today: European shares head for best week since November, inflation data in focus
Brief: Transgene Receives Approval To Start Phase I Trial Of TG6050
Brief: Transgene Q3 Operating Income Up At 2.3 Million Euros
Brief: Transgene: Positive Interim Results Phase II Trial For TG4001 + Avelumab Versus Avelumab In HPV-Positive Anogenital Cancers
Brief: Transgene Updates On TG6002 Phase I Data
Brief: Transgene End-June Operating Loss Widens To 14.8 Million Euros
Brief: Transgene Updates On Clinical Data
Brief: BioInvent, Transgene Announce Collaboration And Supply Agreement With MSD
Transgene rises on encouraging signs from cancer treatment trial
Brief: Transgene And BioInvent Announce Positive Progress For BT-001